Product Name
OTEZLA TABLET STARTER PACK
OTEZLA TABLET 30 MG
Active Ingredient
Apremilast
Product Registrant
AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD
Date of Approval
02/12/2022
Indications:
Otezla is indicated for
· The treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML
Durvalumab
ASTRAZENECA SINGAPORE PTE LTD
12/12/2022
IMFINZI in combination with cisplatin and gemcitabine, is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).
*Evaluated as part of Project Orbis
DENGVAXIA POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
CYD dengue virus serotype 1
CYD dengue virus serotype 2
CYD dengue virus serotype 3
CYD dengue virus serotype 4
SANOFI-AVENTIS SINGAPORE PTE. LTD.
13 December 2022
Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 12 through 45 years of age with test-confirmed previous dengue infection.
New Drug Indication Approvals